Article

MYC overexpression drives poor prognosis and differential sensitivity to treatments according to TP53 status in chronic lymphocytic leukemia

2026-05-18

Abstract excerpt

Chronic lymphocytic leukemia (CLL) is a lymphoid neoplasm with very heterogeneous clinical and biological behavior. Among molecular variables, TP53 alterations are well-established adverse prognostic markers; however, MYC activation, which has been linked to disease progression, has not been completely defined in terms of clinical and biological impact, particularly in relation to TP53 status. Here, we investiga...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 71da7cc9-7c75-5dcc-a766-39f497b554c4
DOI: 10.64898/2026.05.14.724995

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

MYC overexpression drives poor prognosis and differential sensitivity to treatments according to TP53 status in chronic lymphocytic leukemiaDOI 10.64898/2026.05.14.724995Read

The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.Semantic proximity Read

Prognostication in chronic lymphocytic leukemia.Semantic proximity Read

Recent therapeutic advances in chronic lymphocytic leukemiaSemantic proximity Read

Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.Semantic proximity Read

MYC overexpression predicts poor prognosis and correlates with immune infiltration in chronic lymphocytic leukemiaSemantic proximity Read

Optimizing frontline therapy of CLL based on clinical and biological factors.Semantic proximity Read

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.Semantic proximity Read

The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.Semantic proximity Read

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapiesSemantic proximity Read

Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.Semantic proximity Read

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesSemantic proximity Read

Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemiaSemantic proximity Read